Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages

Biomedicine and Pharmacotherapy

Volumn 63, Issue 5, 2009, Pages 351-358

  Suzuki, Eriko ^a   Sugiyama, Chie ^a   Umezawa, Kazuo ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

( ) DHMEQ; Bone marrow derived macrophage; Foam cell; Inducible nitric oxide synthase; Interleukin; NF B

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG STRUCTURE; ESCHERICHIA COLI; FOAM CELL; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; CYCLOHEXANONES; CYCLOOXYGENASE 2; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICE, INBRED ICR; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; STEREOISOMERISM;

EID: 67650803168     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.05.003     Document Type: Article

References (22)

1. Ross J.A., Auger M.J., In Burke B., and Lewis C.E. In: Burke B., and Lewis C.E. (Eds). The macrophage. 2nd ed. The biology of the macrophage 2 (2002), Oxford Medical Publications, Oxford, UK 1-72
2. Nathan C. Inducible nitric oxide synthase: what difference does it make?. J Clin Invest 100 (1997) 2417-2423
3. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2 (2001) 907-916
4. Vila-Del Sol V., and Fresno M. Involvement of TNF and NF-{kappa}B in the transcriptional control of cyclooxygenase-2 expression by IFN-{gamma} in macrophages. J Immunol 174 (2005) 2825-2833
5. Takeda K., and Akira S. Toll-like receptors in innate immunity. Int Immunol 17 (2005) 1-14 Review
6. Liew F.Y., Xu D., Brint E.K., and O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5 (2005) 446-458 Review
7. Akira S. Takeda K.Toll-like receptor signalling. Nat Rev Immunol 4 (2004) 499-511 Review
8. Miyake K. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. Int Immunopharmacol 3 (2003) 119-128 Review
9. Zhou X., Gao X.P., Fan J., Liu Q., Anwar K.N., Frey R.S., et al. LPS activation of Toll-like receptor 4 signals CD11b/CD18 expression in neutrophils. Am J Physiol Lung Cell Mol Physiol 288 (2005) 655-662
10. Tulic M.K., Hurrelbrink R.J., Prêle C.M., Laing I.A., Upham J.W., Le Souef P., et al. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J Immunol 179 (2007) 132-140
11. Paulus S.C., Hirschfeld A.F., Victor R.E., Brunstein J., Thomas E., and Turvey S.E. Common human Toll-like receptor 4 polymorphisms-role in susceptibility to respiratory syncytial virus infection and functional immunological relevance. Clin Immunol 123 (2007) 252-257
12. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104 (2001) 3103-3108
13. Gioannini T.L., and Weiss J.P. Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res 39 (2007) 249-260 Review
14. Doyle S.L. O'Neill LA.Toll-like receptors: from the discovery of NF-kappa B to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 72 (2006) 1102-1113 Review
15. Zhang G., and Ghosh S. Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res 6 (2000) 453-457 Review
16. Matsumoto N., Ariga A., To-e S., Nakamura H., Agata N., Hirano S., et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 10 (2000) 865-869
17. Ariga A., Namekawa J., Matsumoto N., Inoue J., and Umezawa K. Inhibition of TNF-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J Biol Chem 277 (2002) 24625-24630
18. Suzuki E., and Umezawa K. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Biomed Pharmacother 60 (2006) 578-586
19. Suzuki Y., Sugiyama C., Ohno O., and Umezawa K. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor. Tetrahedron 60 (2004) 7061-7066
20. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-γ. Nature 416 (2002) 744-749
21. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3 (2002) 889-901
22. Ohno O., Shima Y., Ikeda Y., Sakurai K., Watanabe K., Kawai Y., et al. Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow. Oncol Res. 15 (2005) 189-197